| Income Statement | 2024-09-30 | |||
|---|---|---|---|---|
| General and administrative expense, total | 5,655 | |||
| Research and development expense, total | 20,527 | |||
| Total operating expenses | 26,182 | |||
| Loss from operations | -26,182 | |||
| Fair value adjustment of warrants | -20,305 | |||
| Interest expense | 1,312 | |||
| Interest income | 793 | |||
| Net loss applicable to common stockholders | -6,396 | |||
| Basic eps | -0.16 | |||
| Diluted eps | -0.16 | |||
| Basic average shares | 39,335,772 | |||
| Diluted average shares | 39,335,772 | |||
Syros Pharmaceuticals, Inc. (SYRS)
Syros Pharmaceuticals, Inc. (SYRS)